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Obesity surgery among people with schizophrenia or bipolar disorder: 
A systematic review of outcomes and recommendations for future research 
Background:  
People with schizophrenia or bipolar disorder (BD) exhibit very high levels of obesity. Little 
is known about the potential benefits/risks of obesity surgery.  We conducted a narrative 
review to summarize the available knowledge on bariatric surgery in people with 
schizophrenia or BD. 
Methods:   
A systematic search was conducted of major electronic databases from inception to October 
2016 for studies investigating bariatric surgery among people with schizophrenia or BD. Data 
were presented in a narrative synthesis and future research strategies proposed. 
Results: 
The electronic database searches identified 44 records. Eight studies (BD, n=265; 
Schizophrenia: n=14) were included with a mean study length of 15.7 months (12-24). Seven 
found that bariatric surgery resulted in weight loss in those with psychiatric disorders with an 
excess weight loss ranging -31% to -70%. Six studies found that weight loss from bariatric 
surgery was similar in people with schizophrenia or BD versus controls. However, most of the 
studies limited their outcomes to only weight loss and did not measure whether obesity 
surgery affected the status and treatment of psychiatric symptoms. Although few adverse 
events were reported among patients with BD, data from two studies demonstrated no 
significant deterioration of psychiatric symptoms post-surgery in people with schizophrenia. 
Conclusions: 
Growing evidence suggests that bariatric surgery may improve short-term weight status 
among people with BD. However, given the paucity of studies for schizophrenia, and the lack 
of information on medium-to long-term results, future large-scale high quality studies are 
required. 
Key words: surgery for obesity; bariatric surgery; severe mental illness; psychosis; 
schizophrenia; bipolar disorder; antipsychotics. 
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INTRODUCTION 
Schizophrenia or bipolar disorder (BD) are severe psychiatric disorders affecting 
about 1-2% of the worldwide population [1–3]. These severe mental illnesses are 
characterized by progressive and chronic deterioration of a wide variety of cognitive, 
psychosocial and physical functioning, which are associated with poorer outcomes. In 
particular, people with psychotic or bipolar disorder are at a 2-3 increased risk of developing 
metabolic disorders including obesity, diabetes, and hyperlipidaemia which accounts for the 
largest portion of the 10-20 years reduction in life expectancy [4,5]. The heightened 
cardiometabolic risk in this population is due to a combination of genetic factors, oxidative 
stress, socio-economic deprivation, lifestyle choices, eating disorders and metabolic effects of 
many psychotropic medications [4,5]. Whilst lifestyle interventions can improve cardio-
metabolic outcomes to some degree, reducing weight on average by 3 kg in participating 
individuals [6], consistent long term data are lacking [7]. Pharmacological interventions such 
as metformin, also only appear to provide small to moderate improvements in metabolic 
outcomes in the short term [8]. 
In the general population, there is evidence that surgery for obesity is the most 
effective treatment for both weight loss and improving obesity-related physical comorbidities 
in severely obese individuals [9]. Recent literature has demonstrated that mental health 
conditions are very common among bariatric surgery patients—in particular, depression and 
binge eating disorder [10–15]. For example, in a recent sample of 393 obese patients, lifetime 
affective disorders, through structured clinical interview, were the most frequent diagnosis 
(total 64.9%; bipolar disorders 35.6% and depressive disorders 29.3%) [16]. In addition, a 
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study and literature review proposed a prevalence of BD in patients seeking bariatric surgery 
ranged from 0.4 to 1.7 for current BD and up to 3.5% for lifetime BD [11] [17]. 
However, little is known about the use and outcomes of bariatric surgery for patients 
with schizophrenia or BD. Indeed, much in line with other physical health care interventions, 
it appears that this patient population is not routinely offered surgical treatment. 
This may in part be due to concerns about ability to adhere to the lifestyle changes 
required and whether that might impact effectiveness and safety, but there is little evidence to 
corroborate such assumptions. In addition, the risk of malabsorption of pharmacological 
treatment after surgery is an important limit and very few studies focused on psychotropic 
drugs monitoring after surgery [18]. In this paper, we conducted a systematic review to 
summarize the available knowledge on bariatric surgery in people with schizophrenia or BD, 
including information on the outcomes and safety of these procedures. Finally, we provide 
recommendations for future research.  
METHODS  
The current brief report systematic review did not follow specific criteria (e.g. PRISMA 
guidelines). To identify studies eligible for this work, we conducted a systematic literature 
search using the main scientific databases Embase, Medline and Psychinfo from inception 
until October 2016. Search terms included the following keywords grouped in various 
combinations: « (bariatric surgery or Roux-en-Y gastric bypass or sleeve gastrectomy or 
laparoscopic adjustable gastric band), and (schizophrenia or bipolar disorder) ». We also 
examined the reference sections from the selected papers to identify any additional relevant 
studies. Inclusion criteria were (a) studies published in an English-language peer-reviewed 
journal; (b) the study enrolled patients with schizophrenia or BD (defined according to 
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recognised criteria, e.g. DSM or ICD, medical diagnoses or validated questionnaire) and (c) 
considered bariatric surgery interventions.  
Two authors conducted independently the searches, selected the included articles and then 
critically reviewed the included studies (YK and AA). Studies were synthesised with a 
narrative summary. We performed methodological quality assessment of included articles 
using the Newcastle Ottawa Scale (NOS). The NOS provides an assessment of the 
methodological quality of non-randomised trials and its content validity and reliability have 
been established [19]. Included studies are judged on 9 items across three key areas: selection 
of the participants, comparability of the participants and outcomes. Each study receives an 
overall score for methodological quality of up to 9 points (one for each item) and scores of 5 
and above are considered to reflect satisfactory study quality. Full descriptive details of the 
included studies are reported in Supplementary Figure 1. 
RESULTS 
The electronic database searches identified 44 records from which 8 met our criteria. 
These eight studies addressed bariatric surgery outcomes among 279 people (mean age 44 
years) with a psychiatric diagnosis of schizophrenia (n=14) or BD (n=265). The mean NOS 
score across the studies was 5.8 (range 5–6). Details of patient characteristics, surgical 
procedures, and timing of assessment are presented in Table 1. Of the 8 studies, 2 were 
prospective cohort studies and 6 involved a group control of patients without psychiatric 
diagnosis. The mean length of follow up was 15.7 months (range 12 to 24). Three studies 
reported information on patients with BD [20–22]; 1 reporting on schizophrenia patients [23]; 
and 4 studies reporting on both [24–27]. 
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1) Weight and metabolic outcomes 
Weight outcomes were reported in 7 studies (n= 135). In most studies, weight loss was 
reported as total weight loss (TWL) or as percent excess weight loss (% EWL), which are 
common metrics for reporting weight loss after bariatric surgery. All of these 7 studies found 
that patients diagnosed with schizophrenia or BD had achieved weight loss outcomes after 
bariatric surgery [20,22–27]. In the six comparative studies, weight loss was comparable 
among people with BD and schizophrenia (n= 117) and controls (n= 857) [20,22–24,26,27]. 
Taken together BD and schizophrenia patients had an average percent EWL ranged from -31 
% to -70% and was comparable to the general bariatric surgery population. 
Regarding specifically schizophrenia patients, Hamoui et al. (n= 5) found no 
significant differences between schizophrenia patients and controls at 6 months, EWL was 
39.5% (range 29.4%- 62.9%) in patients versus 46.9% (range 30.0%-95.5%) in controls [23]. 
Fuchs et al. found that the 4 schizophrenia patients had a 35.7% EWL and was comparable to 
patients without any psychiatric comorbidity at 1 year (p = 0.76) [26]. Finally, using 50% 
EWL as the standard for bariatric surgery success, all the 3 patients met this criterion in the 
non-controlled study of Shelby et al [25]. 
Regarding specifically BD patients, results of six studies (n=121) showed a significant mean 
EWL from baseline to 24 months, ranged from -31% to -70% [20,22,24–27]. 
 
One study examined weight change occurring greater than 24 months after surgery, 
and found no differences in weight between patients with BD and matched control patients 
who attended medical follow-up care at 24 months or longer (average of 52 months) after 
surgery [22]. Moreover, in a 12 months longitudinal study including BD (n=9) and 
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schizophrenia (n=4), psychiatric comorbidities did not affect EWL at any point of follow-up 
when adjusting for age, sex, race, gender, and type of operation [26]. 
Only three studies reported the prevalence of obesity-associated comorbidities 
including type 2 diabetes, cardiovascular disease, hypertension, and dyslipidaemia, among the 
patients but only at baseline [20,21,23]. However, none of the studies described the 
cardiometabolic outcomes after bariatric surgery. 
2) Psychiatric outcomes 
Only 3 studies described the psychiatric outcomes of patients who underwent bariatric 
surgery (n= 167) [21,23,25]. Reports of post-surgery psychiatric status have indicated no 
significant deterioration of psychiatric symptoms in 2 of 3 studies, in the year after surgery.  
Very few patients with schizophrenia have been included in controlled or 
observational studies to date. In the study of Hamoui et al., no patient required psychiatric 
hospitalization following surgery and all continued to live at home with regular psychiatric 
follow-up [23]. In the non-controlled study of Shelby et al., the 3 schizophrenia patients 
experienced exacerbation of psychiatric problems such as agitation, paranoia, auditory 
hallucinations, and also medication changes. One required inpatient psychiatric 
hospitalization [25]. 
Obesity surgery studies in patients with serious mental illness mainly focused on BD.  
In a large study of 144 BD, patients who underwent bariatric surgery were compared with 
1440 matched unexposed controls who were followed for a mean 2 years. The surgical 
intervention was not associated with significant differences in the risk of psychiatric 
hospitalization or change in rate of outpatient visits for psychiatric services [21]. In the non-
controlled study of Shelby et al., among 7 BD patients with known postsurgery psychiatric 
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status (n=7/15), 6 patients suffered from symptom relapse and needed medication changes. 
Only one patient’s decompensation was directly linked to malabsorption in the medical 
record. Six patients required inpatient psychiatric hospitalization [25]. 
3) Adherence and potential adverse events 
One study reported physical adverse events in 2 patients among 5, each developed mild 
anaemia and mild hypocalcaemia), with a similar rate among controls [23]. In the study of 
Shelby, one patient’s decompensation was directly linked to malabsorption in the medical 
record [25]. In another study of patients with a BD who had surgery, hospital re-admissions 
linked to bariatric surgery occurred in only 2 patients within 30 days of surgery (5.7%), both 
for nausea/vomiting and dehydration [22].  
Concerning adherence, one study found no significant difference in the patients’ 
adherence to the follow-up visits between patients with schizophrenia and BD and the 
controls [26]. In the study of Friedman et al, patients with BD attended follow-up care 
(medical and behavioral) at similar frequency as those without psychiatric disorder during the 
first year post-surgery, but were less likely to attend medical follow-up appointments 2 or 
more years post-surgery [22]. Finally, very low rates of loss to follow-up were reported 
among patients with BD and were not significantly different from the control group [21]. 
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DISCUSSION 
The preliminary results of the present review indicate that people with BD or 
schizophrenia can achieve successful short-term weight loss after bariatric surgery. Indeed, 
the excess weight loss was significant in either schizophrenia or BD patients and was 
comparable to weight loss for the general bariatric surgery population (6 studies). However, 
while there is a reasonable amount of data that support these findings for BD patients 
(n=265), current literature data is still lacking for schizophrenia patients (n=14). In addition, 
due to the limited follow-up of the included studies, we are unable to comment on the long-
term outcomes.  
Regarding psychiatric outcomes following surgery, one study (n=18) reported that 10 
patients (BD, n=7, schizophrenia, n=3) suffered from some degree of exacerbation of their 
mental illness post-surgery, which is very high and of concern [25]. However, given the 
absence of a control group of non-surgical schizophrenia patients, these psychiatric courses 
and outcomes could not be compared in this study and we should be cautious in interpreting 
these findings. On the other hand, Ahmed et al. provided evidence that bariatric surgery does 
not adversely affect psychiatric course among stable patients with BD compared to controls. 
Interestingly, bariatric surgery has been associated with a significant decrease of the severity 
of depressive symptoms in one recent meta-analysis [15]. The potential favorable effect on 
the course and outcome of such psychiatric disorders after bariatric surgery remain to be 
studied. Indeed, in this context, bariatric procedures are generally provided to highly selected 
patients. Thus, due to this risk of selection bias, these findings should not be extrapolated to 
all schizophrenia or BD patients, particularly those who are highly incapacitated by their 
illness. 
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However, because individuals with schizophrenia or BD experience fluctuations of 
their symptoms throughout their lives, it should not be assumed, that exacerbations in 
psychiatric problems are negative outcomes due to the bariatric surgery itself. Indeed, the 
psychiatric functioning, severity of symptoms and stability seem of greater importance than 
attempting to differentiate the nuances of such complex diseases. According to an IFSO 
Consensus Statement, “surgery is a contraindication in cases of severe and untreated bipolar 
disorders, and in cases of unstable schizophrenia and psychosis” [9]. However, this should not 
be extrapolated to exclude patients with psychiatric disorders well stabilized and able to 
participate in treatment and long-term follow-up. Indeed, in the absence of a validated 
biomarker of psychiatric illness activity, symptomatic remission and functional restoration are 
the only available markers of wellness in psychiatry [28]. Interestingly, several standardized 
instruments have been developed to measure symptomatic [29] and functional remission 
[30,31] and can be used in routine clinical practice. Of importance, data from two studies 
showed that adherence was similar in people with psychosis versus controls and adverse 
events were few [26]. 
Some limitations need to be considered, including small sample size, particularly for 
schizophrenia patients for which data are nearly inexistent, and limited follow-up. Indeed, 
compared to patients with BD (n=265), the sample of schizophrenia patients was very low 
(n=14) and no strong conclusions can be drawn. Moreover, most of psychiatric diagnoses 
were based on clinical evaluations and only 3 studies used standardized assessment methods. 
Unfortunately, more specific details of the nature of the psychiatric diagnoses, the duration of 
disease and the drug management in these patients were missing. In addition, these studies 
limited their outcomes to only weight loss and did not measure whether obesity surgery 
affected the status and treatment of psychiatric conditions in these patients. Further studies 
addressing these specific psychopathological features are needed, including formal psychiatric 
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assessment, such as the PANSS (Positive and Negative Syndrome Scale). Finally, we did not 
assess the methodological quality of all studies in accordance with the PRISMA guidelines. 
Moreover, whilst we conducted a comprehensive search, it is possible that due to publication 
bias (in that studies with negative findings may be less likely to be published) could have 
influenced the available data. Clearly, future controlled and high quality studies are required 
before any firm conclusions can be made regarding the efficacy and safety of surgical 
interventions to manage obesity among people with BD or schizophrenia.   
 
RECOMMENDATIONS FOR FUTURE RESEARCH 
1) Psychological evaluation before bariatric surgery procedure 
Little is established regarding psychiatric contraindications to bariatric surgery, and 
individual teams have their own psychiatric exclusion criteria [32]. Psychiatric disorders are 
often considered contraindications for bariatric surgery, especially psychosis, affective 
disorders, and personality disorders. Indeed, in a large survey, 31% of mental health 
professionals reported psychotic disorders as a specific psychiatric contraindication [33]. 
Moreover, one of the study included in our review, found that overall, patients diagnosed with 
BD have a relatively low rate for ultimately being approved for bariatric surgery (57%), and 
were less likely to be approved if they had a past psychiatric hospitalization [22]. 
 Additionally, there are no uniform guidelines or protocols to guide the psychological 
assessment for bariatric surgery, clinical interviews forming the main psychological and 
psychiatric evaluation. Screening tools for cognitive function, mood disorders, eating 
disorders, as well as psychopathology tests, are not systematically used, but appear as very 
useful elements of the pre-surgical assessment. It must be remind that the functional impact of 
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psychiatric symptoms may vary considerably among individuals. Indeed, some people with 
psychosis disorders are able to function adequately in their daily lives, while others can be 
seriously impaired by their symptoms. The severity of psychiatric symptoms is more 
influential than the psychiatric diagnosis itself in determining surgery outcome [34]. 
Therefore, the relevant focus of the presurgical evaluation should be on the severity of 
psychiatric symptoms, the patient’s functioning, the stability of the symptoms and the 
treatment in place. In this regard, other important outcomes that deserve further study in these 
patients are the influence of surgery and weight loss outcomes on the psychological health, 
quality of life, and comorbidities of these patients. 
The physical health benefits may lead to consequent improvement in psychiatric 
symptoms. Longitudinal studies revealed significant and maintained improvements in 
psychopathology, quality of life, and self-esteem up to 4 years after obesity surgery [35,36]. 
Furthermore, recent data suggest that adherence to postoperative psychiatric follow-up is 
associated with greater postoperative weight loss in psychotic disorders [37]. 
Finally, patients with psychiatric disorders are at risk of the same medical 
complications of bariatric surgery as all other patients. Distress related to medical 
complications may however exacerbate psychiatric symptoms.  
2) Psychotropic medication management  
Literature regarding psychotropic pharmacokinetic changes in bariatric surgery 
patients is sparse [18]. Weight loss, nutritional status and short-term complications such as 
vomiting, diarrhoea and dehydration may induce changes in drug absorption, metabolism and 
response variability. 
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Growing data exists on the impact of obesity surgery on several drugs such as diabetic, 
hypertensive, and cardiac medications. A reduced drug absorption may occur post-bariatric 
surgery and this effect appears to be drug-specific [38]. However, little is known about the use 
of psychotropic medications after obesity surgery. Recent studies highlight the prevalence of 
antidepressant prescription use in patients before and after obesity surgery and support that 
patients are at risk for reduced drug bioavailability following surgery [39,40]. 
The studies to date do not provide sufficient knowledge on which to base 
recommendations for the management of psychotropic medications in bariatric surgery 
patients. For the malabsorptive procedures, most pharmacokinetic studies focused on Roux-
en-Y gastric bypass (RYGB) with contradictory results. For the restrictive procedures, 
changes in drug absorption seem less likely to occur. However, some case reports have 
described severe lithium toxicity after RYGB and also after sleeve gastrectomy [41].  
Thus, close psychiatric monitoring, individual dose-adjustment and therapeutic 
monitoring (blood level of drug) are highly recommended. Rigorously conducted controlled 
studies are needed to evaluate the effect of bariatric procedures on pharmacokinetic changes 
of psychotropic medication and other high-risk medications [18]. Finally, given the high risk 
of alcohol abuse/dependence and other addictive disorders following bariatric surgery, a 
referral to a specialist in addiction medicine should be also proposed [42,43]. 
CONCLUSION 
People with schizophrenia or BD have extremely high levels of metabolic syndrome 
and obesity, which are leading contributors to the 15-year premature mortality gap. Obesity 
among patients with severe psychiatric illness predicts metabolic syndrome and 
cardiovascular risk, the most frequent cause of premature mortality in this patient 
subpopulation. Bariatric surgery may offer a promising option and may improve weight in 
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these patients with good adherence and few adverse events.  However, the evidence base is in 
its infancy and no firm conclusions can be made regarding the efficacy and safety of bariatric 
surgery until high quality, controlled trials are conducted in people with schizophrenia and 
BD. Recommendations for implementation of future properly designed studies are 
summarized in the table 2. 
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Table 1: Selected studies measuring the metabolic and mental health conditions before and 
after bariatric surgery in people with schizophrenia or bipolar disorder 
 
 
 
LAGB: laparoscopic adjustable gastric banding 
SG: sleeve gastrectomy;  
BPD: biliopancreatic diversion;  
DS: duodenal switch operation 
EWL: excess weight loss;  
TWL: total weight loss; 
* Comparable to the control group 
NA: Not Applicable or Not provided 
Study 
(Country) 
NOS 
score 
Psychiatric disorder 
and sample size 
Diagnosi
s tool 
Mean 
age, 
years 
Group control 
if any 
Surgical 
procedure 
(% or n) 
Timing of 
assessment 
after 
surgery 
Significant weight 
change 
 
Psychopathology outcomes 
Hamoui et 
al, 2004 
(USA)  
5 Schizophrenia (n= 5) 
Clinical 
and 
psycholo
gical 
evaluatio
n 
40 
165 consecutive 
morbidly obese 
patients without 
psychiatric 
diagnosis 
DS: 3 
SG: 1 
BPD: 1 
18 months %EWL= 40* 
No patient required psychiatric 
hospitalization following surgery; all 
patients continue to live at home with regular 
psychiatric follow-up. 
Steinmann 
et al, 2011. 
(USA) 
 
6 
Bipolar disorder 
(n=33) 
 
Clinical 
and 
psycholo
gical 
evaluatio
n 
43 
42 matched 
patients without 
psychiatric 
diagnosis 
RYGB: 100 
% 
1 year %TWL = 31* 
Concurrent psychiatric or psychological 
management during the study period was not 
assessed. 
Ahmed et 
al, 2013. 
(USA) 
6 
Bipolar disorder 
(n=144) 
Clinical 
and 
psycholo
gical 
evaluatio
n 
44 
1,440 matched 
patients without 
psychiatric 
diagnosis 
RYGB: 90% 
LAGB: 7% 
SG: 3% 
1 year NA 
Bariatric surgery was not associated with 
significant differences in the risk of 
psychiatric hospitalization compared with 
1440 matched unexposed patients. 
Hayden et 
al, 2014 
(Australia) 
6 
Bipolar disorder 
(n= 5) 
Schizophrenia (n= 1) 
DSM-IV 
and 
SCID 
45 
93 patients 
without axis I 
psychiatric 
disorder 
LAGB, 100% 2 years %EWL= 40 to 57* NA 
Shelby et 
al, 2015 
(USA) 
5 
Bipolar disorder 
(n=15) 
Schizophrenia (n= 3) 
Clinical 
and 
psycholo
gical 
evaluatio
n 
43 
No group 
control 
RYGB: 66% 
LAGB: 17% 
SG: 17% 
1 year %EWL= 63 
Postsurgery psychiatric status was known on 
10 patients. All 10 patients experienced 
some exacerbation of psychiatric problems 
yet weight loss outcomes were still as 
expected. 
Fuchs et al, 
2015 (USA) 
6 
Bipolar disorder (n=9) 
Schizophrenia (n= 4) 
MADRS 
and  
CES-D 
46 
402 patients 
without any 
psychiatric 
history 
LAGB: 77% 
SG: 23% 
1 year 
%EWL= 36* 
 
No significant difference was found in the 
patients’ adherence to the follow-up visits 
according to their group (PSY or NON-
PSY). 
Thomson et 
al, 2016 
(Canada) 
6 
Bipolar disorder 
(n=17) 
Schizophrenia (n= 1) 
 MINI 
44 
126 patients 
without any 
psychiatric 
history 
RYGB: 90% 
LAGB: 10% 
1 year 
%TWL = 36* 
 
Mental illness severity predicted mental 
HRQOL but not physical HRQOL or 
%TWL. 
Friedman et 
al, 2016 
(USA) 
6 
Bipolar disorder 
(n= 42) 
 
Clinical 
and 
psycholo
gical 
evaluatio
n 
46 
31 nonsurgical 
patients with 
bipolar disorder 
and 29 matched 
control surgical 
patients 
RYGB: 90% 
LAGB: 10% 
2 years %EWL= 70* NA 
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NOS score: the Newcastle Ottawa Scale, which provides an assessment of the methodological quality. 
SCID: Structured Clinical Interview for Diagnostic 
DSM-IV: Statistical Manual of Mental Disorders, 4th Edition 
CES-D Center for Epidemiological Studies Depression  
MADRS: Montgomery-Asberg Depression Rating Scale questionnaires  
MINI: MINI International Neuropsychiatric Interview  
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Table 2: Recommendations for future studies 
 Multidisciplinary approach with access to liaison psychiatry/psychosomatic medicine and 
addiction medicine 
 Propose a screening use and psychiatric referral to characterize psychiatric diagnosis (ICD or 
DSM classification) 
 Use validated and easy reproducible scales to assess baseline mental health, such as the 
Positive and Negative Syndrome Scale (PANSS), the Beck Depression Inventory (BDI), the 
Three-Factor Eating Questionnaire (TFEQ), the Binge Eating Scale (BES) … 
 Ensure studies with long-term follow-up (i.e. > 5 years) 
 Assess adherence to bariatric postoperative guidelines and engagement in the follow-up 
 Offer adherence intervention session  
 Attend closely to the management of psychotropic medications, altering dose if needed, 
monitoring of plasma concentration 
 Continue a close follow-up with a psychiatrist following surgery, with a particular assessment 
of substance use disorders 
 Continue postoperative dietary and psychological support 
 
